Where Big Pharmas Faltered, Stemline Succeeds and Lands FDA Nod in Breast Cancer
Orserdu, a drug from Menarini Group subsidiary Stemline Therapeutics, is now approved for treating breast cancers that carry the ESR1 mutation. The drug is the first approved oral therapy from a class of therapies called selective estrogen receptor degraders (SERDs).